Reason for request
Inclusion on the list of medicines approved for hospital use in the extension of the indication to the treatment of atypical haemolytic uremic syndrome (aHUS).
Clinical Benefit
| Substantial |
The actual benefit of SOLIRIS 300 mg, concentrate for solution for infusion, is substantial in this indication. |
Clinical Added Value
| important |
SOLIRIS 300 mg, an orphan medicine, provides an important improvement in actual benefit (IAB II) compared to standard treatment for patients with aHUS. |
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
91xGhSwcUcTcnLKF
